WO1999025382A1 - Pharmaceutical combination of a cyclooxygenase-2 inhibitor - Google Patents

Pharmaceutical combination of a cyclooxygenase-2 inhibitor Download PDF

Info

Publication number
WO1999025382A1
WO1999025382A1 PCT/EP1998/007537 EP9807537W WO9925382A1 WO 1999025382 A1 WO1999025382 A1 WO 1999025382A1 EP 9807537 W EP9807537 W EP 9807537W WO 9925382 A1 WO9925382 A1 WO 9925382A1
Authority
WO
WIPO (PCT)
Prior art keywords
cyclooxygenase
route
pharmaceutical composition
composition according
compound
Prior art date
Application number
PCT/EP1998/007537
Other languages
French (fr)
Inventor
François CAMBORDE
Alix Cloarec
Eric Nicolai
Jean-Marie Teulon
Original Assignee
Laboratoires Upsa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Upsa filed Critical Laboratoires Upsa
Priority to AU16716/99A priority Critical patent/AU1671699A/en
Publication of WO1999025382A1 publication Critical patent/WO1999025382A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Definitions

  • the object of the present invention is a novel pharmaceutical combination having application notably in the treatment of pain and inflammatory phenomena. More specifically, the invention relates to a pharmaceutical composition comprising a combination of a cyclooxygenase-2 inhibitor and an NMDA antagonist as active principle.
  • Selective cyctooxygenasc-2 (COX-2) inhibitors constitute a novel class of non-steroid analgesic and anti-inflammatory agents. Such compounds have been described for example in the documents WO
  • NMDA N-methyl D aspartate
  • the potentiation effect thus demonstrated renders the use of low doses of each one of the constituent products of the combination possible thereby limiting their possible side effects. Moreover, this combination enables treating pain of very varied origin in a larger number of patients.
  • the pharmaceutical combination in accordance with the present invention will be in a form suitable for an administration :
  • injectable preparations for example
  • Such a composition can be prepared, according to the methods known per se, by inco ⁇ orating the active principle, consisting of the above-mentioned combination, with excipients usually used such as talc, gum arabic, lactose, starch, magnesium stearate, polyvidone, cellulose derivatives, cocoa butter, semisynthetic glycerides, aqueous or non-aqueous vehicles, fats of animal or vegetable origin, glycols, wetting agents, dispersing agents or emulsifiers, silicone gels, certain polymers or co- polymers, preservatives, flavors and coloring agents.
  • excipients usually used such as talc, gum arabic, lactose, starch, magnesium stearate, polyvidone, cellulose derivatives, cocoa butter, semisynthetic glycerides, aqueous or non-aqueous vehicles, fats of animal or vegetable origin, glycols, wetting agents, dispersing agents or emulsifiers, silicone gel
  • any compound having a cyclooxygenase-2 inhibiting activity can be used within the context of the present invention.
  • diaryl methylidene tetrahydrofuran derivatives will be used such as those described in the applications FR 2747123 and FR 2747124 of the Applicant which are inco ⁇ orated herein by reference.
  • a particularly preferred compound is (Z)-3-[l-(4-chlorophenyl)-l-(4- methanesulphonylphenyl)methylene]dihydrofuran-2-one known under the code name of UP 454-21.
  • Dextrometho ⁇ han, ketamine, dizocilpine or even phencyclidine will in particular be cited amongst the NMDA antagonist compounds which can be used within the context of the present invention.
  • Dextrometho ⁇ han a non toxic compound which has been known for a long time, will most particularly be preferred.
  • compositions according to the invention will be in the form of a unit dose.
  • the weight ratio of the cyclooxygenase-2 inhibiting compound to the NMDA antagonist compound will be that which possesses the greater synergy between the two combined compounds, it will be between 0.01 and 10 for the majority of the examples and will be preferably from 0.1 to 3.5.
  • the daily dose which can be used of the various compounds constituting the pharmaceutical combination in accordance with the present invention will of course depend upon the state of the patient to be treated.
  • a suitable daily dose of cyclooxygenase-2 inhibitor will generally be between about 50 mg and about 500 mg.
  • compositions in accordance with the present invention are suitable in the treatment of inflammatory phenomena as well as in the treatment of pain.
  • compositions can also be used within the context of the treatment of bronchial asthma, dysmenorrhea, tendinitis, bursitis, dermatological inflammations such as psoriasis, eczema, burns and dermatitis.
  • compositions can also be used within the context of the treatment of gastrointestinal inflammations, Crohn's disease, gastritis and ulcerative colitis, in the prevention of cancer, especially adenocarcinoma of the colon, in the prevention of neurodegenerative diseases, particularly Alzheimer's disease, in the prevention of cerebral ischaemia and epilepsy, and in the prevention of premature labor.
  • compositions can be used within the context of the treatment of pain symptoms, especially in the treatment of myalgia, articular pain or neuralgia, dental pain, he ⁇ es zoster and migraine, in the treatment of rheumatic complaints and pain of cancerous origin, and also as complementary treatments for infectious and febrile states.
  • the invention further covers a method of therapeutic treatment of mammals, characterized in that it consists in administering a therapeutically effective amount to this mammal of a combination of a cyclooxygenase-2 inhibiting compound and an NMDA antagonist such as described previously.
  • This method especially enables treating inflammatory phenomena and pain.
  • the compound used as an example of a selective cyclooxygenase-2 inhibitor is the compound known under the code name of UP 454-21 of the following general formula
  • results obtained for these tests are expressed in percentage inhibition of the pain reaction with respect to a control group.
  • Test No. 1 Kaolin arthritis test in the rat
  • An inflammation is induced by the administration of a 10% aqueous kaolin suspension into the tibio-femoral joint in the rat.
  • the compounds and the combination studied are administered orally 30 minutes after the injection of kaolin.
  • spontaneous painful behavior (discomfort in walking) is then quoted 5 and 6 hours after the injection of kaolin.
  • the inflammation is induced in the rat by plantar administration of a 2% carrageenin solution.
  • the pain threshold expressed in grams, is then noted down.
  • the compounds and the combination studied are administered orally one hour before the paw pressure test.
  • compositions according to the invention will now be given:
  • Example 1 capsule (size no. 1)
  • Example 4 Ophthalmic solution UP 454-21 0.1%
  • Castor oil (Cremophor EL) 5. %
  • Example 5 Injectable preparation

Abstract

The object of the present invention is a pharmaceutical composition, characterized in that it comprises a combination of a cyclooxigenase-2 inhibitor and an NMDA antagonist as active principle. Application: treatment of pain.

Description

PHARMACEUTICAL COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR
The object of the present invention is a novel pharmaceutical combination having application notably in the treatment of pain and inflammatory phenomena. More specifically, the invention relates to a pharmaceutical composition comprising a combination of a cyclooxygenase-2 inhibitor and an NMDA antagonist as active principle.
Selective cyctooxygenasc-2 (COX-2) inhibitors constitute a novel class of non-steroid analgesic and anti-inflammatory agents. Such compounds have been described for example in the documents WO
94/15932, WO 96/03388 by GD Searle, WO 95/00501 by Merck & Frosst Canada Inc., WO 95/18799, WO 96/08482 by Merck & Co. or even in FR 2747123, FR 2747124 by the Applicant.
Amongst the particularly preferred compounds which have been descπbed m the state of the art,
- 5-bromo-2-[4-fluorophenyl]-3 [4-methanesulphonylphenyljthiophen known under the code name of DuP 697,
- 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol- l-yl]benzene- sulphonamide known under the designation Celecoxib, - (Z)-3-[l-(4-chlorophenyl)-l-(4-methanesulphonylphenyl)methylene]- dihydrofuran-2-one known under the code name UP 454-21, may notably be cited.
Generally, these compounds possess anti-inflammatory and analgesic activities, the latter being demonstrated in various experimental inflammatory pain models. However, it is known that the selective cyclooxygenase-2 inhibitors are inactive or not very active in the non-inflammatory acute pain tests. Ilus, Gans et aτ_, 1. Phann. Exp. Ther. 1990 ; (254) : 180-187 have demonstrated that the DuP 697 product mentioned above is inactive in the phenylbenzoquinone test m the mouse. Furthermore, it is known that the activation of N-methyl D aspartate (NMDA) receptors by neuroexcitatory ammo acids (aspartate, glutamate) is implicated in certain pain processes; NMDA antagonists possess an analgesic activity demonstrated in numerous tests, including chronic pain tests.
It has been discovered, and this constitutes the basis of the present invention, that the combination of a cyclooxygenase-2 inhibitor and an NMDA antagonist compound possesses a significant analgesic effect at doses at which each one of the products constituting this combination is inactive or not very active. The beneficial effect of the combination in accordance with the present invention has been demonstrated both in inflammatory pain models and in noninflammatory acute pain models.
The results obtained have shown that this combination possesses an analgesic activity greater than that of each one of its constituent products used alone at the same dose.
The potentiation effect thus demonstrated renders the use of low doses of each one of the constituent products of the combination possible thereby limiting their possible side effects. Moreover, this combination enables treating pain of very varied origin in a larger number of patients.
Advantageously, the pharmaceutical combination in accordance with the present invention will be in a form suitable for an administration :
- via the oral route, such as simple or coated tablets, capsules or granules, for example;
- via the rectal route, such as suppositories for example
- via the parenteral route, such as injectable preparations for example
- via the ocular route, such as eye lotions or ophthalmic solutions for example; - via the transdermal route
- via the nasal route, such as aerosols and sprays for example; or
- via the auricular route, such as drops for example.
Such a composition can be prepared, according to the methods known per se, by incoφorating the active principle, consisting of the above-mentioned combination, with excipients usually used such as talc, gum arabic, lactose, starch, magnesium stearate, polyvidone, cellulose derivatives, cocoa butter, semisynthetic glycerides, aqueous or non-aqueous vehicles, fats of animal or vegetable origin, glycols, wetting agents, dispersing agents or emulsifiers, silicone gels, certain polymers or co- polymers, preservatives, flavors and coloring agents.
In general, any compound having a cyclooxygenase-2 inhibiting activity can be used within the context of the present invention. Preferably, diaryl methylidene tetrahydrofuran derivatives will be used such as those described in the applications FR 2747123 and FR 2747124 of the Applicant which are incoφorated herein by reference. A particularly preferred compound is (Z)-3-[l-(4-chlorophenyl)-l-(4- methanesulphonylphenyl)methylene]dihydrofuran-2-one known under the code name of UP 454-21. Dextromethoφhan, ketamine, dizocilpine or even phencyclidine will in particular be cited amongst the NMDA antagonist compounds which can be used within the context of the present invention.
Dextromethoφhan, a non toxic compound which has been known for a long time, will most particularly be preferred.
Advantageously, the pharmaceutical compositions according to the invention will be in the form of a unit dose.
In the pharmaceutical combination in accordance with the present invention, the weight ratio of the cyclooxygenase-2 inhibiting compound to the NMDA antagonist compound will be that which possesses the greater synergy between the two combined compounds, it will be between 0.01 and 10 for the majority of the examples and will be preferably from 0.1 to 3.5.
The daily dose which can be used of the various compounds constituting the pharmaceutical combination in accordance with the present invention will of course depend upon the state of the patient to be treated.
A suitable daily dose of cyclooxygenase-2 inhibitor will generally be between about 50 mg and about 500 mg.
The pharmaceutical compositions in accordance with the present invention are suitable in the treatment of inflammatory phenomena as well as in the treatment of pain.
Their use may be cited for example in the treatment of arthritis, especially rheumatoid arthritis, spondylitis, gouty arthritis, osteoarthritis, juvenile arthritis, autoimmune diseases and lupus erythematosus.
These compositions can also be used within the context of the treatment of bronchial asthma, dysmenorrhea, tendinitis, bursitis, dermatological inflammations such as psoriasis, eczema, burns and dermatitis.
These compositions can also be used within the context of the treatment of gastrointestinal inflammations, Crohn's disease, gastritis and ulcerative colitis, in the prevention of cancer, especially adenocarcinoma of the colon, in the prevention of neurodegenerative diseases, particularly Alzheimer's disease, in the prevention of cerebral ischaemia and epilepsy, and in the prevention of premature labor.
Finally, these compositions can be used within the context of the treatment of pain symptoms, especially in the treatment of myalgia, articular pain or neuralgia, dental pain, heφes zoster and migraine, in the treatment of rheumatic complaints and pain of cancerous origin, and also as complementary treatments for infectious and febrile states.
The invention further covers a method of therapeutic treatment of mammals, characterized in that it consists in administering a therapeutically effective amount to this mammal of a combination of a cyclooxygenase-2 inhibiting compound and an NMDA antagonist such as described previously.
This method especially enables treating inflammatory phenomena and pain.
Demonstration of the analgesic properties of the pharmaceutical combination in accordance with the invention.
In order to demonstrate the specific analgesic properties of the pharmaceutical combination in accordance with the present invention, several pharmacological tests have been performed whose experimental protocols and results obtained are given below.
In these tests, the compound used as an example of a selective cyclooxygenase-2 inhibitor is the compound known under the code name of UP 454-21 of the following general formula
Figure imgf000006_0001
while the compound used as the NMDA antagonist is dextromethoφhan.
The results obtained for these tests are expressed in percentage inhibition of the pain reaction with respect to a control group.
Test No. 1 : Kaolin arthritis test in the rat
An inflammation is induced by the administration of a 10% aqueous kaolin suspension into the tibio-femoral joint in the rat. The compounds and the combination studied are administered orally 30 minutes after the injection of kaolin.
The spontaneous painful behavior (discomfort in walking) is then quoted 5 and 6 hours after the injection of kaolin.
The results obtained are represented in Figure I which shows the effect of potentiation exerted by dextromethoφhan upon the cyclooxygenase-2 inhibiting compound (UP 454-21). Test No. 2: Paw pressure test in the carrageenin hyperalgesia model
The inflammation is induced in the rat by plantar administration of a 2% carrageenin solution.
3 hours after this injection, an increasing pressure is exerted upon the animal's paw.
The pain threshold, expressed in grams, is then noted down.
The compounds and the combination studied are administered orally one hour before the paw pressure test.
The results obtained are represented in Figure 2 which shows respectively the effect of potentiation exerted by dextromethoφhan upon the cyclooxygenase-2 inhibiting compound (UP 454-21).
Several examples of pharmaceutical compositions according to the invention will now be given:
EXAMPLES OF UP 454-21/DEXTROMETHORPHAN COMBINATIONS
Example 1 : capsule (size no. 1)
UP 454-21 50 mg
Dextromethoφhan 20 mg
Microcrystallinc cellulose 100 mg
Hydroxypropyl methyl cellulose 10 mg Magnesium stearate 5 mg for a capsule
Example 2: Tablet
UP 454-21 50 mg
Dextromethoφhan 20 mg Microcrystalline cellulose 100 mg
Lactose 100 mg
Hydroxypropyl methyl cellulose 10 mg
Magnesium stearate 5 mg
Hydroxypropyl cellulose 50 mg for a tablet
Example 3 : Suppository
UP 454-21 100 mg Dextromethoφhan 40 mg
Semi-synthetic glyceride (suppocire) 1900 mg for a suppository
Example 4 : Ophthalmic solution UP 454-21 0.1%
Dextromethoφhan 0.06%
Castor oil (Cremophor EL) 5. %
Polysorbate 80 1%
Water preparation for injections q.s.p. 100 %
Example 5 : Injectable preparation
UP 454-21 0.1%
Dextromethoφhan 0.06% PEG 400 30.%
Ethyl alcohol .' 10.%
Water preparation for injections q.s.p. 100 %

Claims

1. A pharmaceutical composition, characterized in that it comprises a combination of a cyclooxygenase-2 inhibitor and an. NMDA antagonist as active principle.
2. The pharmaceutical composition according to claim 1, characterized in that the cyclooxygenase-2 inhibiting compound is (Z)-3-[l-(4-chlorophenyl)l-(4- methanesulphonylphenyl)methyleneldihydrofuran-2-one.
3. The pharmaceutical composition according to claim 1 or 2, characterized in that the above-mentioned NMDA antagonist compound is selected from dextromethoφhan, dizocilpine, ketamine and phencyclidine.
4. The pharmaceutical composition according to one of claims 1 to 3, characterized in that it is in a form suitable for an administration via the oral route, via the parenteral route, via the rectal route, via the ocular route, via the transdermal route, via the nasal route, or via the auricular route.
5. The pharmaceutical composition according to one of claims 1 to 4, characterized in that the weight ratio of the cyclooxygenase-2 inhibiting compound to the NMDA antagonist compound is selected in order to lead to the best synergy between the two combined compounds and is preferably between about 0.01 and about 10 and will preferably be from 0.1 to 3.5.
6. The pharmaceutical composition according to one of claims 1 to 6, characterized in that it is in the form of a unit dose containing from 50 mg to 500 mg of cyclooxygenase-2 inhibiting compound.
PCT/EP1998/007537 1997-11-18 1998-11-17 Pharmaceutical combination of a cyclooxygenase-2 inhibitor WO1999025382A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU16716/99A AU1671699A (en) 1997-11-18 1998-11-17 Pharmaceutical combination of a cyclooxygenase-2 inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9714428A FR2771005B1 (en) 1997-11-18 1997-11-18 NEW PHARMACEUTICAL ASSOCIATION WITH ANALGESIC ACTIVITY
FR97/14428 1997-11-18

Publications (1)

Publication Number Publication Date
WO1999025382A1 true WO1999025382A1 (en) 1999-05-27

Family

ID=9513481

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/007537 WO1999025382A1 (en) 1997-11-18 1998-11-17 Pharmaceutical combination of a cyclooxygenase-2 inhibitor

Country Status (3)

Country Link
AU (1) AU1671699A (en)
FR (1) FR2771005B1 (en)
WO (1) WO1999025382A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000014082A1 (en) * 1998-09-09 2000-03-16 Laboratories Upsa Diarylmethylidene furan derivatives as drugs with anti-inflammatory, analgesic and chemopreventive properties
WO2000029023A1 (en) * 1998-11-12 2000-05-25 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with nmda-blockers for treating pain

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038957A1 (en) 2001-08-15 2005-02-02 Pharmacia Corp COMBINATION THERAPY FOR CANCER TREATMENT
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013483A1 (en) * 1994-10-27 1996-05-09 Merck Frosst Canada Inc. Stilbene derivatives useful as cyclooxygenase-2 inhibitors
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
WO1996019469A1 (en) * 1994-12-21 1996-06-27 Merck Frosst Canada Inc. Diaryl-2-(5h)-furanones as cox-2 inhibitors
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
WO1996031509A1 (en) * 1995-04-04 1996-10-10 Glaxo Group Limited IMIDAZO[1,2-a]PYRIDINE DERIVATIVES
WO1996036623A1 (en) * 1995-05-18 1996-11-21 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5h)-furanones as cox-2 inhibitors
WO1997014691A1 (en) * 1995-10-13 1997-04-24 Merck Frosst Canada Inc. (methylsulfonyl)phenyl-2-(5h)-furanones as cox-2 inhibitors
US5639780A (en) * 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
WO1996013483A1 (en) * 1994-10-27 1996-05-09 Merck Frosst Canada Inc. Stilbene derivatives useful as cyclooxygenase-2 inhibitors
WO1996019469A1 (en) * 1994-12-21 1996-06-27 Merck Frosst Canada Inc. Diaryl-2-(5h)-furanones as cox-2 inhibitors
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
WO1996031509A1 (en) * 1995-04-04 1996-10-10 Glaxo Group Limited IMIDAZO[1,2-a]PYRIDINE DERIVATIVES
WO1996036623A1 (en) * 1995-05-18 1996-11-21 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5h)-furanones as cox-2 inhibitors
US5639780A (en) * 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
WO1997014691A1 (en) * 1995-10-13 1997-04-24 Merck Frosst Canada Inc. (methylsulfonyl)phenyl-2-(5h)-furanones as cox-2 inhibitors
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000014082A1 (en) * 1998-09-09 2000-03-16 Laboratories Upsa Diarylmethylidene furan derivatives as drugs with anti-inflammatory, analgesic and chemopreventive properties
WO2000029023A1 (en) * 1998-11-12 2000-05-25 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with nmda-blockers for treating pain

Also Published As

Publication number Publication date
FR2771005B1 (en) 2002-06-07
FR2771005A1 (en) 1999-05-21
AU1671699A (en) 1999-06-07

Similar Documents

Publication Publication Date Title
JP2018048189A (en) Drug combinations and uses in treating a coughing condition
AU2002309429B2 (en) Pharmaceutical formulation for the efficient administration of apomorphine, 6aR-(-)-N-propyl-norapomorphine and their derivatives and pro-drugs thereof
JP4817495B2 (en) Pain control with exogenous cannabinoids
CN106304835A (en) Sgc stimulant
KR19980064024A (en) Pharmaceutical composition
US6015797A (en) Adenosinergic agonist containing pharmaceutical composition with analgesic activity
JP2008518896A (en) Combination of nicotinic acetylcholine α7 receptor antagonist
MX2007009187A (en) The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome.
US20220184075A1 (en) Pharmaceutical composition containing hdac6 inhibitor as active ingredient for prevention or treatment of itching
JP2005505539A (en) Composition comprising a CB1 receptor antagonist for the treatment of Parkinson's disease and a product that activates brain dopaminergic neurotransmission
CA3187588A1 (en) Transdermal pharmaceutical formulations of cannabinoids
JP6762312B2 (en) NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
WO1999021585A1 (en) Pharmaceutical combination of a cyclooxigenase-2 inhibitor and acetaminophen or an opiate
WO2011133212A1 (en) Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders
EA015483B1 (en) Use of a p38 kinase inhibitor for treating psychiatric disorders
JP2575569B2 (en) Use of glycine / NMDA receptor ligand for the treatment of drug dependence and withdrawal symptoms
WO1999025382A1 (en) Pharmaceutical combination of a cyclooxygenase-2 inhibitor
US20070105940A1 (en) Method for treating pain
JP2013500943A (en) Compositions and methods for the treatment of Parkinson's disease
KR20110005836A (en) Use of a combination of udenafil and alfuzosin or oxybutynin for the treatment of overactive bladder
WO2007047881A2 (en) Method for treating neuropathic pain
EP3741369A1 (en) Synergistic pharmaceutical combination of the active enantiomer s-ketorolac tromethamine and tramadol chlorhydrate
AU2018258970B2 (en) Idalopirdine-based combinatorial therapies of Alzheimer's disease
JP2010524906A (en) Use of 4-cyclopropylmethoxy-N- (3,5-dichloro-1-oxidepyridin-4-yl) -5- (methoxy) pyridine-2-carboxamide for the treatment of movement failure associated with Parkinson's disease
EA011926B1 (en) Oral antidepressant formulation comprising acetylsalicylic acid to accelerate onset of action

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA